慢性心力衰竭患者血浆尾加压素Ⅱ水平的变化及其临床意义

目的 本文旨在研究尾加压素Ⅱ（urotensinⅡ,UⅡ）在慢性心力衰竭患者中含量变化及其临床意义。方法 入选20例正常人（对照组）、88例心力衰竭患者（心力衰竭组：心功能Ⅱ级23例、Ⅲ级29例、Ⅳ级36例）为研究对象,采用放射免疫分析法测定血浆UⅡ浓度,竞争酶免疫分析法测定血浆BNP浓度,超声心动图测定左室射血分数（EF）、左室质量指数（LVMI）等参数。结果 正常对照组和心力衰竭组间年龄、性别等基线资料无明显差异;心力衰竭组血浆UⅡ浓度显著低于正常对照组（分别为3.45±0.97 pg/ml和5.73±0.69 pg/ml,P〈0.001）,而血浆BNP浓度显著高于正常对照组（分别为512±233pg/ml和65±26pg/ml,P〈0.001）;血浆UⅡ浓度与LVEF呈显著正相关（r=0.62,P〈0.001）,与血浆BNP浓度呈显著负相关（r=-0.79,P〈0.01）,与左心室质量指数（LVMI）显著负相关（r=-0.36,P〈0.01）。结论慢性心力衰竭患者血浆UⅡ浓度显著降低,并且与左室射血分数正相关,左心室质量指数负相关。

Change of Plasma Urotensin in Patients with Chronic Heart Failure

Objective To compare plasma urotensin Ⅱ（ UⅡ） concentration in patients with chronic heart failure（CHF） and healthy control, and to explore its clinical significance. Methods Eighty-eight patients with CHF and 20 healthy controls were enrolled in the study. Plasma concentration of UⅡ were measured by radioimmunoassay. BNP were measured by enzyme-linked immunosorbent assay. Left ventricular ejection fraction and Left ventricular mass index were measured by echocardiography. Results There were no difference in sex and age between healthy controls and CHF patients. Plasma concentration of UⅡ in CHF group was significant lower than healthy group（3.45±0.97 pg/ml vs.5.73±0.69 pg/ml, P0.001）, and plasma BNP level was significant higher than healthy group（512±233pg/ml vs. 65±26pg/ml, P0.001）. Plasma UⅡ concentration was correlated with LVEF（r=0.62, P0.001）. Plasma U Ⅱ concentration was correlated with BNP（r=-0.79, P0.001）. Also Plasma U Ⅱconcentration was correlated with LVMI（r=-0.36, P0.01）. Conclusion Plasma UⅡ concentration was decreased significantly in chronic heart failure patients. The levels of plasma UⅡ were correlated with abnormal LVEF and LVMI, which may have a clinical significance to early diagnosis and evaluated treatment efficacy of CHF.